ArticleAngewandte Chemie (International ed. in English)2025
Metabolic Engineering of the 5-Aminolevulinate Biosynthetic Pathway in E. coli Improves Efficiency of Hemoprotein-Based Biocatalysis.
Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Engineering a heme-dependent tryptophan hydroxylase pathway inSynthetic and systems biotechnology · 2026Article
- Metabolic Engineering of the 5-Aminolevulinate Biosynthetic Pathway in E. coli Improves Efficiency of Hemoprotein-Based Biocatalysis.Angewandte Chemie (International ed. in English) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Biocatalysis using heme-dependent enzymes provides a powerful synthetic platform to facilitate a variety of chemical transformations required for organic synthesis. Despite recent advances in biocatalysis, recombinant expression systems for hemoproteins leave much room for improvement due to the strict regulation of heme biosynthesis in the host organism. To develop an efficient cofactor supplementation system for the expression of active holohemoproteins, we describe metabolic engineering of the heme biosynthetic pathway in E. coli. Through incorporation of a heterogeneous C4 pathway involving 5-aminolevulinic acid synthase of Paracoccus denitrificans, it was found that the concentrations of 5-aminolevulinic acid and heme in the engineered cells are increased during cultivation, and the expression level of the holohemoproteins is significantly improved. Notably, the heme content in the engineered cells is even higher than that produced by conventional cultivation methods, which add 5-aminolevulinic acid into the culture medium. Furthermore, we also demonstrate the application of this engineered E. coli cells in whole-cell and lysate-based biocatalysis using various types of heme-dependent enzymes. Considering the recent demand for biocatalysis, the system developed in this study will serve as a new practical and versatile platform for hemoprotein-based biocatalysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.